tiprankstipranks
Ardent Health Partners, Inc. (ARDT)
NYSE:ARDT
US Market
ARDT
Ardent Health Partners, Inc.
RESEARCH TOOLSreports
Want to see ARDT full AI Analyst Report?

Ardent Health Partners, Inc. (ARDT) Stock Forecast & Price Target

103 Followers
See the Price Targets and Ratings of:

ARDT Analyst Ratings

Moderate Buy
9Ratings
Moderate Buy
5 Buy
3 Hold
1 Sell
Based on 9 analysts giving stock ratings to
Ardent
Health Partners, Inc.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ARDT Stock 12 Month Forecast

Average Price Target

$12.36
▲(24.69% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for Ardent Health Partners, Inc. in the last 3 months. The average price target is $12.36 with a high forecast of $14.00 and a low forecast of $9.00. The average price target represents a 24.69% change from the last price of $9.91.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","9":"$9","11":"$11","13":"$13","15":"$15"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.357142857142858,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.36</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,9,11,13,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.22,9.587692307692308,9.955384615384617,10.323076923076924,10.69076923076923,11.05846153846154,11.426153846153847,11.793846153846154,12.161538461538463,12.52923076923077,12.896923076923077,13.264615384615386,13.632307692307693,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.22,9.461318681318682,9.702637362637363,9.943956043956044,10.185274725274725,10.426593406593406,10.66791208791209,10.90923076923077,11.150549450549452,11.391868131868133,11.633186813186814,11.874505494505495,12.115824175824176,{"y":12.357142857142858,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.22,9.203076923076924,9.186153846153847,9.16923076923077,9.152307692307692,9.135384615384616,9.118461538461538,9.101538461538462,9.084615384615384,9.067692307692308,9.05076923076923,9.033846153846154,9.016923076923076,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.41,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.73,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.22,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.67,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.08,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.56,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.79,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.83,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.59,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.48,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.67,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.15,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.22,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$14.00Average Price Target$12.36Lowest Price Target$9.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on ARDT
Kevin Fischbeck
Bank of America Securities
Bank of America Securities
$10→$9
Sell
-9.18%
Downside
Reiterated
06/09/26
Ardent Health price target lowered to $9 from $10 at BofAArdent Health price target lowered to $9 from $10 at BofA
Morgan Stanley Analyst forecast on ARDT
Craig Hettenbach
Morgan Stanley
Morgan Stanley
$12
Hold
21.09%
Upside
Reiterated
06/08/26
Analysts Offer Insights on Healthcare Companies: Moderna (NASDAQ: MRNA), Ardent Health Partners, Inc. (NYSE: ARDT) and Gilead Sciences (NASDAQ: GILD)
UBS Analyst forecast on ARDT
A.J. Rice
UBS
UBS
$13.5
Buy
36.23%
Upside
Reiterated
06/03/26
Analysts Offer Insights on Healthcare Companies: Ardent Health Partners, Inc. (NYSE: ARDT), Tactile Systems Technology (NASDAQ: TCMD) and Oric Pharmaceuticals (NASDAQ: ORIC)
Goldman Sachs Analyst forecast on ARDT
Scott Fidel
Goldman Sachs
Goldman Sachs
$12
Hold
21.09%
Upside
Reiterated
06/03/26
Analysts Offer Insights on Healthcare Companies: Ardent Health Partners, Inc. (NYSE: ARDT), Vera Therapeutics (NASDAQ: VERA) and Spyre Therapeutics (NASDAQ: SYRE)
Guggenheim Analyst forecast on ARDT
Jason Cassorla
Guggenheim
Guggenheim
$13
Buy
31.18%
Upside
Reiterated
06/03/26
Guggenheim Sticks to Its Buy Rating for Ardent Health Partners, Inc. (ARDT)
KeyBanc Analyst forecast on ARDT
Matthew Gillmor CFA
KeyBanc
KeyBanc
―
Hold
―
Reiterated
06/03/26
Analysts Offer Insights on Healthcare Companies: CVRx (NASDAQ: CVRX), Ardent Health Partners, Inc. (NYSE: ARDT) and Amphastar Pharmaceuticals (NASDAQ: AMPH)
Truist Financial Analyst forecast on ARDT
Jailendra Singh
Truist Financial
Truist Financial
―
Buy
―
Reiterated
06/03/26
Analysts Offer Insights on Healthcare Companies: Ardent Health Partners, Inc. (NYSE: ARDT), Lemaitre Vascular (NASDAQ: LMAT) and Gilead Sciences (NASDAQ: GILD)
Leerink Partners Analyst forecast on ARDT
Whit Mayo
Leerink Partners
Leerink Partners
$15→$14
Buy
41.27%
Upside
Reiterated
05/15/26
Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (NASDAQ: AQST) and Ardent Health Partners, Inc. (NYSE: ARDT)
RBC Capital Analyst forecast on ARDT
Ben Hendrix
RBC Capital
RBC Capital
$13
Buy
31.18%
Upside
Reiterated
05/07/26
RBC Capital Remains a Buy on Ardent Health Partners, Inc. (ARDT)
Stephens Analyst forecast on ARDT
Unknown Analyst
Stephens
Not Ranked
Stephens
$14
Buy
41.27%
Upside
Reiterated
03/06/26
Stephens Reaffirms Their Buy Rating on Ardent Health Partners, Inc. (ARDT)
Mizuho Securities Analyst forecast on ARDT
Ann Hynes
Mizuho Securities
Mizuho Securities
$20→$12
Buy
21.09%
Upside
Reiterated
12/18/25
Ardent Health price target lowered to $12 from $20 at MizuhoArdent Health price target lowered to $12 from $20 at Mizuho
J.P. Morgan Analyst forecast on ARDT
Benjamin Rossi
J.P. Morgan
J.P. Morgan
$15→$12
Hold
21.09%
Upside
Reiterated
11/24/25
Ardent Health price target lowered to $12 from $15 at JPMorganArdent Health price target lowered to $12 from $15 at JPMorgan
Loop Capital Markets Analyst forecast on ARDT
Timothy Greaves
Loop Capital Markets
Loop Capital Markets
$17
Buy
71.54%
Upside
Reiterated
11/14/25
Loop Capital Markets Reaffirms Their Buy Rating on Ardent Health Partners, Inc. (ARDT)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on ARDT
Kevin Fischbeck
Bank of America Securities
Bank of America Securities
$10→$9
Sell
-9.18%
Downside
Reiterated
06/09/26
Ardent Health price target lowered to $9 from $10 at BofAArdent Health price target lowered to $9 from $10 at BofA
Morgan Stanley Analyst forecast on ARDT
Craig Hettenbach
Morgan Stanley
Morgan Stanley
$12
Hold
21.09%
Upside
Reiterated
06/08/26
Analysts Offer Insights on Healthcare Companies: Moderna (NASDAQ: MRNA), Ardent Health Partners, Inc. (NYSE: ARDT) and Gilead Sciences (NASDAQ: GILD)
UBS Analyst forecast on ARDT
A.J. Rice
UBS
UBS
$13.5
Buy
36.23%
Upside
Reiterated
06/03/26
Analysts Offer Insights on Healthcare Companies: Ardent Health Partners, Inc. (NYSE: ARDT), Tactile Systems Technology (NASDAQ: TCMD) and Oric Pharmaceuticals (NASDAQ: ORIC)
Goldman Sachs Analyst forecast on ARDT
Scott Fidel
Goldman Sachs
Goldman Sachs
$12
Hold
21.09%
Upside
Reiterated
06/03/26
Analysts Offer Insights on Healthcare Companies: Ardent Health Partners, Inc. (NYSE: ARDT), Vera Therapeutics (NASDAQ: VERA) and Spyre Therapeutics (NASDAQ: SYRE)
Guggenheim Analyst forecast on ARDT
Jason Cassorla
Guggenheim
Guggenheim
$13
Buy
31.18%
Upside
Reiterated
06/03/26
Guggenheim Sticks to Its Buy Rating for Ardent Health Partners, Inc. (ARDT)
KeyBanc Analyst forecast on ARDT
Matthew Gillmor CFA
KeyBanc
KeyBanc
―
Hold
―
Reiterated
06/03/26
Analysts Offer Insights on Healthcare Companies: CVRx (NASDAQ: CVRX), Ardent Health Partners, Inc. (NYSE: ARDT) and Amphastar Pharmaceuticals (NASDAQ: AMPH)
Truist Financial Analyst forecast on ARDT
Jailendra Singh
Truist Financial
Truist Financial
―
Buy
―
Reiterated
06/03/26
Analysts Offer Insights on Healthcare Companies: Ardent Health Partners, Inc. (NYSE: ARDT), Lemaitre Vascular (NASDAQ: LMAT) and Gilead Sciences (NASDAQ: GILD)
Leerink Partners Analyst forecast on ARDT
Whit Mayo
Leerink Partners
Leerink Partners
$15→$14
Buy
41.27%
Upside
Reiterated
05/15/26
Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (NASDAQ: AQST) and Ardent Health Partners, Inc. (NYSE: ARDT)
RBC Capital Analyst forecast on ARDT
Ben Hendrix
RBC Capital
RBC Capital
$13
Buy
31.18%
Upside
Reiterated
05/07/26
RBC Capital Remains a Buy on Ardent Health Partners, Inc. (ARDT)
Stephens Analyst forecast on ARDT
Unknown Analyst
Stephens
Not Ranked
Stephens
$14
Buy
41.27%
Upside
Reiterated
03/06/26
Stephens Reaffirms Their Buy Rating on Ardent Health Partners, Inc. (ARDT)
Mizuho Securities Analyst forecast on ARDT
Ann Hynes
Mizuho Securities
Mizuho Securities
$20→$12
Buy
21.09%
Upside
Reiterated
12/18/25
Ardent Health price target lowered to $12 from $20 at MizuhoArdent Health price target lowered to $12 from $20 at Mizuho
J.P. Morgan Analyst forecast on ARDT
Benjamin Rossi
J.P. Morgan
J.P. Morgan
$15→$12
Hold
21.09%
Upside
Reiterated
11/24/25
Ardent Health price target lowered to $12 from $15 at JPMorganArdent Health price target lowered to $12 from $15 at JPMorgan
Loop Capital Markets Analyst forecast on ARDT
Timothy Greaves
Loop Capital Markets
Loop Capital Markets
$17
Buy
71.54%
Upside
Reiterated
11/14/25
Loop Capital Markets Reaffirms Their Buy Rating on Ardent Health Partners, Inc. (ARDT)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ardent Health Partners, Inc.

3 Months
Jason CassorlaGuggenheim
Success Rate
8/9 ratings generated profit
89%
Average Return
+11.68%
Copying Jason Cassorla's trades and holding each position for 3 Months would result in 88.89% of your transactions generating a profit, with an average return of +11.68% per trade.
1 Year
Jason CassorlaGuggenheim
Success Rate
5/9 ratings generated profit
56%
Average Return
-4.91%
Copying Jason Cassorla's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of -4.91% per trade.
2 Years
Jason CassorlaGuggenheim
Success Rate
5/9 ratings generated profit
56%
Average Return
-5.37%
Copying Jason Cassorla's trades and holding each position for 2 Years would result in 55.56% of your transactions generating a profit, with an average return of -5.37% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ARDT Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
3
4
3
3
2
Buy
3
6
6
10
7
Hold
0
2
2
4
6
Sell
0
1
1
1
1
Strong Sell
0
0
0
0
0
total
6
13
12
18
16
In the current month, ARDT has received 9 Buy Ratings, 6 Hold Ratings, and 1 Sell Ratings. ARDT average Analyst price target in the past 3 months is 12.36.
Each month's total comprises the sum of three months' worth of ratings.

ARDT Financial Forecast

ARDT Earnings Forecast

Next quarter’s earnings estimate for ARDT is $0.25 with a range of $0.21 to $0.32. The previous quarter’s EPS was $0.28. ARDT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ARDT has Performed in-line its overall industry.
Next quarter’s earnings estimate for ARDT is $0.25 with a range of $0.21 to $0.32. The previous quarter’s EPS was $0.28. ARDT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ARDT has Performed in-line its overall industry.

ARDT Sales Forecast

Next quarter’s sales forecast for ARDT is $1.64B with a range of $1.61B to $1.69B. The previous quarter’s sales results were $1.60B. ARDT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ARDT has Performed in-line its overall industry.
Next quarter’s sales forecast for ARDT is $1.64B with a range of $1.61B to $1.69B. The previous quarter’s sales results were $1.60B. ARDT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ARDT has Performed in-line its overall industry.

ARDT Stock Forecast FAQ

What is ARDT’s average 12-month price target, according to analysts?
Based on analyst ratings, Ardent Health Partners, Inc.’s 12-month average price target is 12.36.
    What is ARDT’s upside potential, based on the analysts’ average price target?
    Ardent Health Partners, Inc. has 24.69% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ARDT a Buy, Sell or Hold?
          Ardent Health Partners, Inc. has a consensus rating of Moderate Buy which is based on 5 buy ratings, 3 hold ratings and 1 sell ratings.
            What is Ardent Health Partners, Inc.’s price target?
            The average price target for Ardent Health Partners, Inc. is 12.36. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $14.00 ,the lowest forecast is $9.00. The average price target represents 24.69% Increase from the current price of $9.91.
              What do analysts say about Ardent Health Partners, Inc.?
              Ardent Health Partners, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of ARDT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.